RCS - Moon Surgical - Moon Surgical Mark Toland Independent Board Member

Siemens AGAnnouncement

15/11/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221115:nRSO5050Ga&default-theme=true

RNS Number : 5050G  Moon Surgical  15 November 2022

Moon Surgical Announces Appointment of Mark Toland as Independent Board Member

 

PARIS and SAN FRANCISCO, November 15, 2022 -- Moon Surgical
(http://www.moonsurgical.com/) , a pioneer in collaborative robotics, today
announced the appointment of Mark Toland as an independent board member. With
over 25 years of senior executive leadership experience in the medical device
industry and in the field of robotics, Toland joins the board of directors as
the company works to finalize the development of its first product and prepare
for the commercial launch of the Maestro Robotic System.

 

Mark Toland is currently the Chief Executive Officer at MMI, a surgical
robotics company developing a platform for microsurgery. Prior to joining MMI,
Toland served as President and Chief Executive Officer of Corindus, a global
leader in endovascular robotics, that was acquired by Siemens Healthineers for
$1.1 billion. He was also an independent board member to Cardiologs, which was
acquired by Philips in late 2021.

 

"I am thrilled to welcome Mark to our expanded team at Moon Surgical," said
Anne Osdoit, CEO of Moon Surgical, and a Partner in Sofinnova Partners'
medtech accelerator, MD Start. "His independent, astute mind and expertise in
US commercialization strategy in our sector will be invaluable in helping us
reach our next goals."

 

Founded in Paris in 2019 by Pr. Brice Gayet and incubated by Sofinnova MD
Start (https://sofinnovapartners.com/strategy/md-start) , Moon Surgical has
shown its prowess at speed and innovation with early systems already fully
functional and driven by more than thirty surgeons across two continents and
multiple clinical indications.

 

"Moon's approach to how laparoscopic surgeons should be assisted and empowered
in the operating room is truly unique and has the potential to make the
Maestro System an absolute must-have in every surgical practice," commented
Mark Toland. "I am honored to be a part of the team that is revolutionizing
minimally invasive surgery with adaptive robotics and look forward to working
together to continue its rapid growth."

 

Small, adaptable, and integrated into existing clinical workflows, Maestro is
designed to support surgeons and patients in the 18.8 million soft-tissue
surgery procedures not currently supported by telerobotic systems every year.

 

About Moon Surgical

Moon Surgical, based in Paris, France, and San Carlos, California, believes
the future of the operating room lies in the hands of the empowered surgeon.

 

By equipping surgeons with complete control, renewed confidence, and
technology adaptable to any situation they encounter, Moon Surgical strives to
improve efficiency in operating rooms and provide better surgical care for
patients. The minimalistic, co-manipulation Maestro Robotic System uses
tomorrow's technology to deliver these vital skills to surgeons, today.

 

www.moonsurgical.com (http://www.moonsurgical.com)

 

Contact

Investors and Media: info@moonsurgical.com (mailto:info@moonsurgical.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFMFIIEESEIF